Big pharma will definitely pay more for RAC to have this in place as they will continue their research in the US when they buy us out and now they can benefit from what the FDA has granted us.
- Forums
- ASX - By Stock
- Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
Big pharma will definitely pay more for RAC to have this in...
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.60 |
Change
-0.130(7.51%) |
Mkt cap ! $275.1M |
Open | High | Low | Value | Volume |
$1.74 | $1.74 | $1.60 | $300.2K | 183.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4352 | $1.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.61 | 2047 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 623 | 1.605 |
5 | 14596 | 1.600 |
1 | 1046 | 1.585 |
3 | 31115 | 1.580 |
1 | 638 | 1.565 |
Price($) | Vol. | No. |
---|---|---|
1.610 | 3019 | 2 |
1.615 | 2248 | 1 |
1.620 | 1450 | 1 |
1.630 | 10000 | 1 |
1.640 | 500 | 1 |
Last trade - 15.53pm 27/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online